The Swiss PolyPeptide Group AG, a global CDMO for peptide- and oligonucleotide-based active pharmaceutical ingredients (APIs) and Numaferm GmbH, a Düsseldorf-based German biotech company specialized in process development and production of peptides and proteins have signed a Preferred Partner Collaboration Agreement for peptide development and production.
The strengths of both parties are now to be combined for the sustainable development and production of peptides: On one hand Numaferm's biochemical production platform and expertise for the sustainable production of peptides, on the other hand PolyPeptide's cGMP manufacturing process, regulatory expertise, and market access.
The Numaferm GmbH (Düsseldorf, NRW) uses proprietary technologies and products protected globally by over 50 patents to offer specialized biochemical production of peptides and proteins. Numaferm's resource-saving technologies and processes were awarded the first NRW Environmental Economy Prize in 2020.
Christian Schwarz, CEO at Numaferm, commented: “Our mission is to support our partners with best-in-class peptide and protein manufacturing technologies, covering the entire value chain. The collaboration with PolyPeptide is a major milestone giving our clients a clear route to clinical trial and commercial materials and access to industry-leading regulatory expertise. This collaboration underscores the value of our proprietary biosynthesis platform for the peptide industry.”
The PolyPeptide Group, whose origins date back to 1952, today operates a network of six cGMP-certified production facilities in Europe, the USA and India. PolyPeptide (SIX: PPGN) shares have been listed on the SIX Swiss Exchange since the beginning of 2021.
Olivier Ludemann-Hombourger, Director Global Innovation and Technology at PolyPeptide, commented: “We are impressed by Numaferm’s track record, expertise, and their innovative biochemical production platform for next-level biosynthesis peptide manufacturing. It complements our Green Chemistry initiatives and allows us to broaden the scope of our manufacturing offering. We look forward to exploring the development of suitable peptide candidates together.”
Market Status XETR ⓘ
XETR
The market status window is an indication regarding the current technical availability of the trading system. It indicates whether news board messages regarding current technical issues of the trading system have been published or will be published shortly.
Please find further information about incident handling in the Emergency Playbook published on the webpage under Data & Tech > Information Channels > Emergency procedures. Detailed information about incident communication, market re-opening procedures and best practices for order and trade reconciliation can be found in the chapters 4.2, 4.3 and 4.5, respectively. Concrete information for the respective incident will be published during the incident via newsboard message
We strongly recommend not to take any decisions based on the indications in the market status window but to always check the production news board for comprehensive information on an incident.
An instant update of the Market Status requires an enabled up-to date Java™ version within the browser.